drugset / Trial / NCT00799773
Evaluating the Effectiveness of Adding Rituximab to Standard Treatment for Thrombotic Thrombocytopenic Purpura (TTP)
Phase 3
Terminated
3 enrolled
Carelon Research
Genentech, Inc. · collabNational Heart, Lung, and Blood Institute (NHLBI) · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
Thrombotic thrombocytopenic purpura (TTP) is a rare disorder that causes blood clots to form in blood vessels. The main treatment for TTP is plasma exchange, in which affected patients receive transfusions of plasma, the liquid part of blood, from healthy donors. This study will examine the effectiveness of an antibody, rituximab, in combination with plasma exchange, at improving the immune response in people with TTP and decreasing the recurrence of TTP.
Timeline
- Start
- 2009-04
- Primary completion
- 2010-02
- Completion
- 2010-02
Outcome
Outcome not reported
Stopped (Enrollment): “Low enrollment rate”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | Prednisone | Other / unclassified | 1 mg/kg | — |